by barry101 | Sep 3, 2024 | Press Releases
HOUSTON, Sept. 3, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today...
by barry101 | Aug 26, 2024 | Press Releases
Live webcast on Wednesday, August 28th at 3:40 PM ET HOUSTON, Aug. 26, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug...
by barry101 | Aug 19, 2024 | Press Releases
$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON, Aug. 19, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...
by barry101 | Aug 16, 2024 | Press Releases
$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON, Aug. 16, 2024 /PRNewswire-PRWeb/ — Moleculin Biotech, Inc., (Nasdaq: MBRX)...
by barry101 | Aug 14, 2024 | Press Releases
– Positive outcome from End of Phase 1B/2 Meeting with FDA – Company proceeding with a pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the...
